Tag: address

Investors' backing bolsters Relativity Networks' ability to meet the insatiable demand for a data transmission technology that hyperscalers require for the AI-powered economy. ORLANDO, Fla.,...

The Flex complements the original WaveCore, which penetrates thick concrete floors and walls in the interior, to lower the cost of roof-to-indoor, building-to-building and...

HOLON, Israel, July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug...

SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the oral health profession, will...

SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the oral health profession, will...

Group CFO of SingularityNET Foundation since 2020, scaling the ecosystem from $40M USD market cap to multi-billion USD market cap $90M USD in digital...

Leverages AI to offer real-time support, raise service requests, and simplify complex transaction queries MUMBAI, India, July 23, 2025 /PRNewswire/ -- Axis Trustee Services Limited (ATSL),...

CEO Dr. Michael Fübi's visit reinforces India's growing role in shaping global compliance standards, sustainable industries, and future-ready workforce development. BANGALORE, India, July 23,...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

SINGAPORE, July 23, 2025 /PRNewswire/ -- On 17 July 2025, Giti Tire was honoured to be conferred as a 3 heart Company of Good at...

82km of drilling and $9M invested in resource development and exploration in Q4, FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...

WOBURN, Mass., July 22, 2025 /PRNewswire/ -- Micro Medical Solutions (MMS), a leading innovator in minimally invasive vascular solutions for Critical Limb Ischemia (CLI),...